The Utility of Intensified Case Finding Combined With a Package of Novel TB Diagnostics Using a Mobile Clinic in Africa

Tuberculosis Clinical Trial

— XACT  

Official title:

The Utility of Intensified Case Finding Combined With a Package of Novel TB Diagnostics Using a Mobile Clinic in Africa- a Randomized Controlled Trial (XACT)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01990274
• Other study ID #: XACT.2011.10800.003
• Status: Completed
• Phase: N/A
• First received: October 24, 2013
• Last updated: November 24, 2015
• Start date: October 2013
• Est. completion date: April 2015

Study information

• Verified date: November 2015
• Source: University of Cape Town
• Contact: n/a
• Is FDA regulated: No
• Health authority: South Africa: Human Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare two different methods of intensified tuberculosis (TB) case finding in the community. These methods all involve the use of a mobile clinic to reach people with TB symptoms who are not able to readily access clinic services. A standard diagnostics package consisting of smear microscopy and culture (with smear result available the next day) will be compared with a novel diagnostics package involving point-of-care sputum GeneXpert MTB/RIF performed at a mobile or conventional clinic (with same day result), sputum culture, and lateral flow urinary lipoarabinomannan (LAM) testing (in HIV +ve subjects only). The primary outcome is a comparison between the number of culture +ve subjects on TB treatment in each group at the end of two months. A secondary aim is an evaluation of the accuracy and feasibility of GeneXpert performed in a mobile clinic. Additional study aims include using chest X-rays obtained during the study to develop and validate of an computer-aided diagnosis (CAD) software package for TB (together with collaborators in the Netherlands), as well as establishing whether LAM is detectable at sub-ELISA concentrations in the urine of those with TB.

Description:

Despite recent advances in diagnosis and the availability of effective anti-tuberculous treatment TB remains one of the world's most devastating infectious disease, with a global prevalence of more than 14 million in 2006. In high burden communities with the co-localised HIV epidemic, a major problem hampering control efforts and promulgating the TB epidemic is the large reservoir of undiagnosed TB disease. This comprises over 50% of the total TB burden. HIV-infection with its atypical yet infectious presentation where immunity is attenuated worsens this undetected reservoir. Thus, there is a large case load in the community that do not access health care or do so late in the course of the disease and there is thus ongoing disease transmission within the community. If this caseload in not addressed then the TB epidemic will never be controlled.

Intensified case finding seeks to address this problem. Intensified case finding is a strategy to identify and treat people with TB who have not sought diagnostic services on their own initiative. By contrast, passive case finding is only able to identify people with TB presenting to health care facilities. In 2008 the WHO and Stop TB partnership identified intensified case-finding as one of four core TB prevention strategies necessary to meet the sixth Millennium Development Goal of halving the prevalence of TB by 2015. To date, a number of studies have illustrated the success of intensified case finding to increase case-detection rates (especially in HIV-infected populations) and to shorten time to diagnosis thereby limiting attendant morbidity and mortality.

Given both the importance and resource-intensive nature of intensified case finding it is essential that the optimal, operationally feasible and most cost-effective screening strategy be used. To date, screening strategies have varied widely across studies but all have used a combination of symptom screening, radiological (CXR) and microscopy-centre based laboratory diagnostics (smear microscopy and, if available and cost permitting, TB culture). This is a major shortcoming as it is now well established that these standard diagnostic tools perform sub-optimally especially in high HIV prevalent settings. With the recent development of a number of novel TB diagnostic tools with superior performance compared to conventional modalities, and the potential for point-of-care (POC) and point-of-treatment usage, it is imperative that intensified case-finding strategies be reviewed. The 2010 updated WHO "Guidelines for intensified tuberculosis case finding and isoniazid preventive therapy for people living with HIV in resource constrained settings" recommends the use of a clinical algorithm for intensified case finding programmes for adults and adolescents living with HIV and it is important that the incremental diagnostic benefit together with the feasibility and cost-effectiveness of these novel TB diagnostic tools be assessed for use in intensified case finding programmes within the context of these updated guidelines.

In 2009, Cepheid released the Xpert® MTB/RIF Assay, which is the only system able to deliver answers directly from unprocessed samples by combining on-board preparation of the sample with real-time PCR in less than 2 hours. Additionally, the Xpert® MTB/RIF Assay allows for simultaneous on-demand molecular testing for the detection of M.tb and RIF resistance. The GeneXpert™ system consists of a GeneXpert instrument, personal computer and disposable fluidic cartridges. The system combines cartridge-based sample preparation with amplification and detection in a fully integrated and automated nucleic acid analysis instrument. GeneXpert has been shown to be an accurate tool for the rapid diagnosis of tuberculosis in both smear-positive and smear-negative samples (with a single Xpert test having a sensitivity of ~ 70% in smear-negative samples. A large demonstration study of Gene Xpert based at microscopy-centres is currently underway and preliminary data appear promising. However, GeneXpert technology has not been used as part of a screening strategy for intensified case finding and its operational feasible as a point-of-treatment diagnostic technology based in a mobile clinic has not yet been assessed.

In our recent review we have proposed urinary LAM as a useful "rule in" test for TB in HIV-infected subjects with advanced immune-suppression. Additionally, the recent development of a point-of-care urine LAM lateral flow strip test - the Determine TB® - with preliminary results suggesting equivalent performance to the LAM ELISA make it an appealing diagnostic for high HIV prevalence areas. A recent study has shown urine LAM to be more sensitive than smear-microscopy in an ARV clinic-based TB screening study. The use of the Determine TB® lateral flow strip test has not been studied as part of an intensified case finding strategy for population-based surveys. The Determine TB® lateral flow test will be used for screening of HIV-infected patients at point-of-care within the community and subsequent TB clinic referral for sputum-based diagnostics.

The XACT study has a randomised control study design to evaluate the impact of a package of novel TB diagnostic tools in the community using a mobile unit compared to standard intensive-case finding methods. The feasibility of performing new TB diagnostics at the point-of-care will be examined to determine if the proportion of patients identified, initiating, and completing TB treatment, is greater compared to the standard diagnostic arm. Further, the cost-effectiveness of TB cases detected and successfully completing treatment between study arms can also be investigated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 875
• Est. completion date: April 2015
• Est. primary completion date: April 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Community participant willing to complete community-based symptom screening, urine testing and/or undergo TB diagnostic tests at the local TB clinic.

2. Provision of informed consent.

3. HIV-negative adults (older than 18 years) with 1 or more of the following:

• cough = 2 weeks

• loss of weight

• persistent fever = 2 weeks and/or

• a single recorded temp > 38°C

• night sweats

• generalized fatigue

• hemoptysis or

• chest pain

4. Any HIV+ve adult (older than 18 years).

Exclusion Criteria:

1. Inability to provide informed consent (e.g. mentally impaired).

2. Patients self-presenting to the TB clinics.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Tuberculosis

Intervention

Procedure:
• GeneXpert MTB/RIF assay
Automated nucleic-acid amplification test (fully integrated) test for TB
• Smear microscopy
Smear microscopy involve sputum smear with either ziehl-neelsen or auramine-O staining of slides and light or fluorescence microscopy reading

Locations

Country	Name	City	State
Italy	University of Sassari	Sassari
Netherlands	Radboud University	Nijmegen
South Africa	University of Cape Town	Cape Town	Western Province
Zimbabwe	University of Zimbabwe	Harare

Sponsors (4)

Lead Sponsor	Collaborator
University of Cape Town	Radboud University, Università degli Studi di Sassari, University of Zimbabwe

Countries where clinical trial is conducted

Italy,  Netherlands,  South Africa,  Zimbabwe, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comparison of novel intensive-case finding diagnostic tools to standard intensive-case finding strategy	The proportion of culture-positive TB cases initiating TB treatment in each study arm.	2 months	No
Secondary	The proportion of culture-positive TB cases completing TB treatment in each study arm	The number of patients that are enrolled, randomized to a study arm, diagnosed with TB, and completing TB treatment.	6 months	No
Secondary	Feasibility of performing Xpert MTB/RIF at the point-of-care in a mobile unit using an alternative power supply	Feasibility indicators for the performance of Xpert in a mobile unit. These include turn-around-time, user appraisal and assessments and performance comparisons between mobile clinic and laboratory-based Xpert MTB/RIF.	6 months	No
Secondary	Cost per TB case detected between study arms	Documentation of patient costs for TB diagnosis.	6 months	No
Secondary	Cost per TB case successfully completing treatment between study arms	Documentation of patient costs for completing TB treatment.	6 months	No
Secondary	Determining whether LAM is present at sub-ELISA concentrations using mass spectroscopy of urine samples from TB patients	Urine from subjects will be used to verify whether LAM is present in the urine of HIV-infected persons with TB at sub-ELISA concentrations using mass spectrometry. LAM standards will be used in spiked urine samples to evaluate limit of detection and specificity.	6 months	No
Secondary	Validating the electronic chest X-ray scoring system for Computer Aided Diagnostics (CAD) of TB	The method employs an automatic scoring algorithm to interpret digitalized chest x-rays. The system is suited to x-rays being done in remote areas where medical expertise is not available.	6 months	No

External Links

•   XACT website